Robin Soto
RN, MSN, FNP-BC
Introduction
Location : San Diego, CA, USA
Specialty : MASLD
BIO
Robin Soto is a Family Nurse Practitioner with over 25 years of clinical experience. She earned her Master's in Nursing from The Johns Hopkins School of Nursing, where she was both a National Health Service Corps Scholar and a Peace Corps Fellow. Robin has served as a Hepatology Nurse Practitioner at UC San Diego Health Hepatology since 2016.
As an active member of the Eliminate Hep C San Diego County initiative, Robin serves on the Access, Testing, Treatment and Prevention committee, where she helped develop the Recommendations report and Implementation Plan adopted by the San Diego Board of Supervisors. Her excellence has been recognized with the 2019 Mid-Career Hepatology Associates Scholar Award from AASLD and the 2018 Patrons of Nursing Professional Certification Scholarship from UC San Diego Health.
Robin contributes to the UC San Diego Health Interdisciplinary Practice Committee and is an accomplished national speaker, presenting at prestigious events including Digestive Disease Week and The Liver Meeting. In 2022, she was selected as the inaugural speaker for UC San Diego Health APP Grand Rounds.
When not advancing hepatology care, Robin enjoys traveling with friends in search of great wine and food, spending time with her rescue dogs, and exploring San Diego with her husband.
Highlighted Events
GHAPP Regional
May 15 @ 12:00 pm - 12:00 pm PST
Speakers: Sherona Bau, MSN, ACNP, CNS UCLA Health Los Angeles, CA Jill Olmstead, DNP, NP-C, FAANP Providence Healthcare Fullerton, C..
GHAPP Regional
May 29 @ 12:00 pm - 12:00 pm MST
Speakers: Christina Hanson, FNP-C South Denver Gastroenterology Michelle Barnett, PA Peak Gastroenterology..
GHAPP Eighth Annual Conference
September 04 @ 12:00 pm - September 06 @ 12:00 pm MDT
About the 2025 GHAPP Conference The GHAPP conference is the only conference specifically designed by advanced practice providers (APPs) for the pur..
Pacific Northwest GI & Liver Update
October 03 @ 12:00 pm - October 04 @ 12:00 pm PST
The 2025 Pacific Northwest GI and Liver Conference will deliver focused educational updates highlighting clinically relevant advances in the managemen..
MASLD-MASH Content Featuring Robin
Updates On Approved Treatments for MASH
Join Robin Soto, NP, for an engaging session at the MASH Boot Camp during the 2024 GHAPP National Conference as she provides updates on improved treatments for metabolic-associated steatohepatitis (MASH). Robin dives into the mechanisms of action, key clinical data, and prescribing guidelines for current therapies, including groundbreaking updates from the MAESTRO-NASH study. She also explores the game-changing potential of FDA-approved therapies like Resmetirom, offering insights into its efficacy, safety, and impact on patients with at-risk fibrosis.
Watch Now
Management of Life Style Modification
This video focuses on the comprehensive management of patients with metabolic-associated steatohepatitis (MASH), emphasizing lifestyle modifications, dietary adjustments, and exercise strategies. Key topics include the importance of addressing risk factors like diet, exercise habits, and alcohol intake, as well as referrals to medically supervised weight loss clinics or bariatric surgery for advanced cases. The speaker highlights the benefits of the Mediterranean diet, intermittent fasting, and avoiding ultra-processed foods while discussing the role of resistance training to combat sarcopenia and maintain muscle mass. Practical advice and tailored recommendations ensure a holistic approach to managing MASH and improving patient outcomes.
Watch Now
Third Step of Life Style Management
This video provides a comprehensive overview of emerging pharmacologic treatments for metabolic-associated steatohepatitis (MASH) and their tailored applications based on patient profiles. Topics include FDA-approved therapies, drugs in advanced clinical trials (such as semaglutide and lanifibranor), and the potential for combination treatments targeting both steatohepatitis and fibrosis. The speaker emphasizes the importance of patient-specific approaches considering metabolic profiles, obesity, and diabetes status, alongside lifestyle interventions. Additionally, the video discusses the evolving interdisciplinary care model and highlights the exciting progress in non-invasive testing and treatment advancements for F2-F3 fibrosis.
Watch Now
Approved Medication for MASH/NASH
This video provides detailed guidance on selecting and monitoring patients for emerging therapies targeting advanced fibrosis (F2-F3) in NASH. Key topics include contraindications for patients with cirrhosis, considerations for concomitant medications, and dose adjustments for statins. The video outlines ideal candidates based on specific thresholds for VCTE, MRE, ELF scores, and other non-invasive tests while emphasizing the importance of ruling out portal hypertension and other liver diseases. It also reviews a stepwise monitoring approach, focusing on tolerability at three months and efficacy assessments at six and twelve months, with an emphasis on histologic and non-invasive test improvements.
Watch Now
Types of Diet for the Treatment of MASLD
This video explores comprehensive strategies for managing metabolic-associated steatohepatitis (MASH), focusing on fibrosis risk stratification, lifestyle modifications, and pharmacologic interventions. Learn about dietary recommendations like the Mediterranean diet, exercise guidelines emphasizing resistance training, and the role of intermittent fasting and processed food avoidance. The video also highlights weight loss targets, diabetes management, and emerging therapies such as GLP-1 receptor agonists and bariatric surgery, all aimed at improving liver health and patient outcomes.
Watch Now
NITs to Identify High Risk MASH Patients
Explore advancements in non-invasive diagnostics and risk stratification for liver fibrosis and MASH. This video highlights tools like FIB-4, transient elastography, and innovative scoring systems (e.g., FAST and Agile) to identify and predict outcomes for high-risk patients. Learn about serum biomarkers, updated guidelines, and the role of lifestyle interventions alongside targeted therapies for managing metabolic risks and advancing care in hepatology.
Watch Now
What is Resmetirom and how does it work to treat MASH?
Thank you to Madrigal for sponsoring the Medication Review Video Module. In this GHAPP Medication Review video, Robin Soto, a board-certified nurse practitioner at UC San Diego Health Hepatology, explains the mechanism of action of Resmetirom, the first and only FDA-approved drug for the treatment of MASH in adults with mild to moderate fibrosis (F2-F3). Robin describes how Resmetirom, a liver-directed, thyroid hormone receptor beta agonist, targets liver fat accumulation, promoting fatty acid oxidation and improving cholesterol metabolism. She highlights its anti-inflammatory effects and ability to reduce liver fibrosis by selectively activating receptors in the liver, while minimizing systemic side effects. For more information, visit the GHAPP website and ACE app.
Watch Now
MASH Bootcamp Q&A
In this interactive Q&A session, a panel of liver disease experts discusses key challenges in diagnosing and treating metabolic dysfunction-associated steatohepatitis (MASH) using non-invasive testing and the latest therapeutic advancements. The panel explores the role of FibroScan, ELF scores, and cardiometabolic risk factors in diagnosing fibrosis, especially in patients with limited access to MRI or VCTE-based assessments. They also discuss how serologic testing can be a viable alternative in resource-limited settings and when a liver biopsy may not be necessary for diagnosis. The discussion highlights the FDA approval criteria for Resmetirom, its limitations in F4 patients, and practical strategies for determining treatment eligibility. The experts address real-world challenges, including diagnosing MASH in rural areas, evaluating confounding factors in fibrosis assessment, and ensuring comprehensive liver disease workups to rule out autoimmune conditions.
Watch Now